Business Wire

Tigo Energy Expands Predict+ for Utility Analytics as Platform Approaches 10X Annual Growth

10.2.2025 15:00:00 CET | Business Wire | Press release

Share

Predict+ platform surpasses 140,000 meters under management globally, expands advanced feature set, and brings machine learning-powered energy consumption and production prediction to utilities in Europe and North America.

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a set of powerful enhancements to the Predict+ platform that gives utilities deep insight into grid demand, renewable generation, and energy market dynamics. Designed to enhance the accuracy, scalability, and robustness of energy forecasting with up to 97.5% accuracy through machine learning and artificial intelligence, the platform leverages smart meter consumption data to predict precise grid production and consumption forecasts. Predict+ helps energy providers streamline operations, reduce volatility, and maximize performance. Since the first quarter of 2024, the Predict+ platform has grown from 15,000 to 140,000 meters under management and covers a total of 600 GWh of energy today.

Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. The platform delivers actionable intelligence that improves load forecasting accuracy while reducing manual workload, with data intervals ranging from yearly, monthly, daily, and down to by-the-minute data resolution. Predict+ includes the following primary functional domains:

  • Market Insights: an accurate view of the near-term energy market trends combined with customer-internal data in an easy to consume, customizable dashboard
  • Customer Insights: a combination of market and cost data used to evaluate the financial impact of expanding into new markets or acquiring high-value customers
  • Profit Analysis: predicts and documents actual revenues from end-customers​ with integrated billing and invoicing functions taking existing processes from days, down to minutes.
  • Regulatory Support: automatically generates forecast plans and securely transmits the plans to regulatory agencies in select regions

“The Predict+ platform doesn't only allow our customers to lower operating costs and streamline workflows, it actually drives higher returns on investment and more resilient, intelligent renewable energy infrastructure,” said Zvi Alon, chief executive officer at Tigo Energy. “As Predict+ expands into Europe and North America, we are bringing machine learning to energy analytics and predictions to a new standard for energy forecasting. As energy generation becomes more diverse and markets become increasingly dynamic, Predict+ offers a competitive edge by bringing grid stability and true foresight to utility operators.”

Predict+ has the ability to quickly recalibrate demand and load forecasts in response to external disruptions—such as COVID-19 and extreme weather events—which gives grid operators a distinct competitive edge. Existing customers continue to validate the platform’s real-world value by expanding their usage, adding modules, and scaling capacity. Predict+ stands apart from traditional forecasting methods by leveraging advanced algorithms that reduce volatility, improve accuracy, and streamline operations, often outperforming legacy approaches like spreadsheets by up to 11%, with approximately 3% deviation from actual. By consistently delivering higher accuracy with reduced manual intervention, Predict+ has become a trusted solution for energy providers looking to optimize grid performance through forecasting.

To learn more about Predict+ or participate in a platform demonstration, contact the Tigo team here and select “Predict+ info/demo” in the subject menu.

About Tigo Energy

Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210484457/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye